Skip to content

Ruta graveolens,a Homoeopathic medicine in the treatment of Colorectal cancer

Phytochemical screening of ruta graveolens mother tincture and clinical effectiveness of ruta graveolens 30c in comparison with individualized homoeopathic medicine on colorectal cancer patients in respect to carcinoembryonic antigen:an open label non randomised clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067749
Enrollment
40
Registered
2024-05-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C20- Malignant neoplasm of rectum

Interventions

Intervention1: Ruta graveolens 30C in one arm and Individualised Homoeopathic medicine in another arm: Ruta graveolens 30C,a Homoeopathic medicine will be prescribed as per the homoeopathic principle

Sponsors

National Institute Of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of all genders, different religions and socioeconomic groups. Age between 18-80 years. Histologically confirmed Colorectal cancer patients. In case the medicine does not provide relief or aggravate the patients condition and the disease progresses further, immediate care will be taken by providing the proper dose of medicine Patients having Colorectal Malignancy of any histological type at any stage except those mentioned under exclusion. Patients who are otherwise untreated and have opted for homoeopathic treatment. Patients who have already had Surgery, Radiotherapy or Chemotherapy but now intend to undergo homoeopathic treatment. Patient willing to give written consent for participating in the study and complete follow-up during study.

Exclusion criteria

Exclusion criteria: Patients who continue to be under Chemotherapy or Radiotherapy. Pregnant and Lactating women. Patients not willing to undergo any investigation, even after advised. Individuals unwilling to get solely homoeopathic treatment. Patients in the terminal stage of illness. Diagnosed cases of unstable mental or psychiatric illness.

Design outcomes

Primary

MeasureTime frame
Tumor biomarker CEA will be evaluated Timepoint: At baseline, after 3 months and 6 months of treatment

Secondary

MeasureTime frame
The response of the patients will be observed and improvement in Quality of Life will be assessed with EORTC QLQ-CR29 scaleTimepoint: at baseline, after 3 months & 6 months of treatment

Countries

India

Contacts

Public ContactDr Gitasri Pal

National Institute Of Homoeopathy

drgitasripal@gmail.com8910624248

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026